Compare Moderna, Inc. (MRNA) vs Tilray Brands Inc (TLRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Tilray Brands Inc — how do they compare? Moderna, Inc. trades at $63.62 (market cap $24.18B), while Tilray Brands Inc trades at $4.69 (market cap $649.42M). The key difference: Moderna, Inc. is far larger — about 37.2× Tilray Brands Inc's market cap, and Moderna, Inc. is trading nearer its 52-week high, Tilray Brands Inc nearer its low. Which is the better fit depends on your goals.
| MRNA | TLRY | |
|---|---|---|
Market Cap | $24.18B | $649.42M |
Sector | Health | Health |
52-Week High | $81.80 | $21.00 |
52-Week Low | $22.36 | $3.88 |
Enterprise Value | $20.33B | $816.55M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $63.70, up 6.5% recently, with a bullish technical signal and strong moving average support. Despite negative net income margins, the company beat Q2 2026 EPS estimates and secured FDA approval for its mRNA flu vaccine, mFLUSIVA, signaling diversification beyond COVID-19. Revenue has declined from pandemic peaks but is projected to stabilize around $2.2B in 2026.
The outlook is mixed: near-term catalysts from new vaccine approvals and pipeline progress offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus is cautious with a hold-heavy rating, reflecting uncertainty over profitability timelines amid ongoing R&D investments.
TLRY trades at $4.68, up 5.88% today, amid bullish technical signals and news-driven momentum. The company reported record fiscal 2026 revenue of $915 million but posted a net loss of $121 million, with profitability challenges persisting. Recent developments include new product launches and partnerships, while analyst sentiment remains mixed with a majority hold rating.
Outlook hinges on revenue growth and margin improvement, but risks include sustained losses, high debt, and competitive pressures. The stock offers speculative appeal if execution improves, yet volatility and dilution concerns warrant caution for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Tilray Brands Inc
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →
